Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C189- Malignant neoplasm of colon, unspecified Health Condition 3: C20- Malignant neoplasm of rectum Health Condition 4: C169- Malignant neoplasm of stomach, unspecified
Conditions
Interventions
Intervention1: Topical Henna Gel: Two fingertip unit of topical preparation will be applied on the soles and one fingertip unit on the palms from the first day of chemotherapy with capecitabine and co
Sponsors
JIPMER Intramural Resarch Fund
Eligibility
Inclusion criteria
Inclusion criteria: Patients of both gender older than 18 years. Patients attending Regional Cancer Centre, JIPMER who are diagnosed with cancer (breast cancer, Colorectal cancer and stomach cancer). Patients who are planned for capecitabine based chemotherapy regimen (1000-1250mg/m2 twice daily).
Exclusion criteria
Exclusion criteria: Patients who received capecitabine previously. Patients with pre-existing peripheral neuropathy and other dermatological disorders Patients who are on low dose capecitabine regimen (less than 1000mg per m2 twice daily).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of topical henna preparation on the prevention of capecitabine induced hand foot syndrome in cancer patients.Timepoint: Every three weeks for nine weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The adverse reactions of topical preparation of henna in cancer patients with capecitabine induced hand foot syndrome.Timepoint: Every three weeks for nine weeks;The time taken for the appearance of capecitabine induced hand foot syndrome in cancer patients.Timepoint: Every three weeks for nine weeks | — |
Countries
India
Contacts
Public ContactB Bhanupriya
JIPMER
Outcome results
None listed